Combretastatin A4 phosphate: Background and current clinical status

Expert Opinion on Investigational Drugs

Volumn 13, Issue 9, 2004, Pages 1171-1182

  Young, Scott L ^a   Chaplin, David J ^a  

^a OXiGENE Inc   (United States)

Author keywords

Combretastatin; Oncology; Ophthalmology; Vascular disrupting; Vascular targeting

Indexed keywords

BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; COLCHICINE; COMBRETASTATIN A4 PHOSPHATE; CYCLOPHOSPHAMIDE; DILAUDID CR; DOXORUBICIN; FLUOROURACIL; GADOLINIUM PENTETATE; HYDROMORPHONE; IRINOTECAN; LORAZEPAM; MELPHALAN; METOPROLOL SUCCINATE; NALOXONE; NITROPRUSSIDE SODIUM; PACLITAXEL; PROPRANOLOL; TAXANE DERIVATIVE; TUBULIN; VINCA ALKALOID;

ABDOMINAL PAIN; ALOPECIA; ANTINEOPLASTIC ACTIVITY; APNEA; AREA UNDER THE CURVE; ATAXIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMBRETUM; DEHYDRATION; DIARRHEA; DIPLOPIA; DISTRIBUTION VOLUME; DIZZINESS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG STORAGE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSPNEA; ECG ABNORMALITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEAD AND NECK TUMOR; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART OUTPUT; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; HYPOXIA; INTESTINE ISCHEMIA; ISCHEMIC HEART DISEASE; KIDNEY CANCER; LETHARGY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MUSCLE WEAKNESS; NECK PAIN; NEUROLOGIC DISEASE; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PAIN; PARESTHESIA; POWDER; PR INTERVAL; PROSTATE CANCER; PULMONARY HYPERTENSION; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RADIOIMMUNOTHERAPY; RESPIRATION DEPRESSION; REVIEW; SINGLE DRUG DOSE; SINUS TACHYCARDIA; SKIN TINGLING; ST SEGMENT DEPRESSION; STOMATITIS; STRIDOR; STRUCTURE ACTIVITY RELATION; SYNCOPE; T WAVE; TACHYCARDIA; THYROID CARCINOMA; VISUAL IMPAIRMENT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STILBENES;

EID: 4544277194     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.9.1171     Document Type: Review

References (59)

1. PETTIT GR, CRAGG GM, SINGH SB: Antineoplastic agents, 122. Constituents of Combretum caffrum. J. Nat. Prod. (1987) 50(3):386-391.
2. PETTIT GR, SINGH SB, HAMEL E, LIN CM et al.: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia (1989) 45(2):209-211.
3. LIN CM, SINGH SB, CHU PS, DEMPCY RO et al.: Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol. (1988) 34(2):200-208.
4. LUDFORD RJ, Factors determining the action of colchicine on tumour growth. Br. J. Cancer (1948) 2:75-86.
5. BAGULEY BC, HOLDAWAY KM, THOMSEN LL, ZHUANG L et al.: Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer (1991) 27(4):482-487.
6. BOYLAND E, BOYLAND ME: Studies in tissue metabolism. IX The action of colchicine and B typhosus extract. Biochem. J. (1937) 31:454-460.
7. DARK GG, HILL SA, PRISE VE, TOZER GM et al.: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. (1997) 57(10):1829-1834.
8. TOZER GM, PRISE VE, WILSON J, LOCKE RJ et al.: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. (1999) 59(7):1626-1634.
9. BLAKEY DC, WESTWOOD FR, WALKER M, HUGHES GD et al.: Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models. Clinical Cancer Res. (2002) 8(6):1974-1983.
10. HORI K, SAITO S, NIHEI Y, SUZUKI M et al.: Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J. Cancer Res. (1999) 90(9):1026-1038.
11. HORI K, SAITO S, KUBOTA K: A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br. J. Cancer (2002) 86(10):1604-1614.
12. GALBRAITH SM, CHAPLIN DJ, LEE F, STRATFORD MR et al.: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. (2001) 21(1A):93-102.
13. CHAPLIN DJ, DOUGHERTY GJ: Tumour vasculature as a target for cancer therapy. Br. J. Cancer (1999) 80(Suppl.):57-64.
14. TOZER GM, KANTHOU C, PARKINS CS, HILL SA: The biology of the combretastatins as vascular targeting agents. Int. J. Exp. Pathol. (2002) 83(1):21-38.
15. PETTIT GR, TEMPLE C Jr, NARAYANAN VL, VARMA R et al.: Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. (1995) 10(4):299-309.
16. PETTIT GR, RHODES MR: Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des. (1998) 13(3):183-191.
17. WOODS JA, HADFIELD JA, PETTIT GR, FOX BW et al.: The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br. J. Cancer (1995) 71(4):705-711.
18. LIN CM, HO HH, PETTIT GR, HAMEL E: Antimitotic natural products combretastatin A-4 and combretastatin A: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry (1989) 28(17):6984-6991.
19. DZIBA JM, MARCINEK R, VENKATARAMAN G, ROBINSON JA et al.: Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid (2002) 12(12):1063-1070.
20. BOEHLE AS, SIPOS B, KLICHE U, KALTHOFF H et al.: Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann. Thorac. Surg. (2001) 71(5):1657-1665.
21. EL-ZAYAT AA, DEGEN D, DRABEK S, CLARK GM et al.: In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs (1993) 4(1):19-25.
22. BOHLE AS, LEUSCHNER I, KALTHOFF H, HENNE-BRUNS D: Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation. Int. J. Cancer (2000) 87(6):838-843.
23. GROSIOS K, HOLWELL SE, McGOWN AT, PETTIT GR et al.: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer (1999) 81(8):1318-1327.
24. BEAUREGARD DA, THELWALL PE, CHAPLIN DJ, HILL SA et al.: Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br. J. Cancer (1998) 77(11):1761-1767.
25. EIKESDAL HP, SCHEM BC, MELLA O, DAHL O: The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. Int. J. Radiat. Oncol. Biol. Phys. (2000) 46(3):645-652.
26. HORSMAN MR, EHRNROOTH E, LADEKARL M, OVERGAARD J: The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int. J. Radiat. Oncol. Biol. Phys. (1998) 42(4):895-898.
27. MAXWELL RJ, NIELSEN FU, BREIDAHL T, STODKILDE-JORGENSEN H et al.: Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI. Int. J. Radiat. Oncol. Biol. Phys. (1998) 42(4):891-894.
28. CHAPLIN DJ, PETTIT GR, HILL SA: Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. (1999) 19(1A):189-195.
29. CHAPLIN DJ, HORSMAN MR: The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies. Radiother. Oncol. (1994) 30(1):59-65.
30. LI L, ROJIANI A, SIEMANN DW: Targeting the tumor vasculature with combretastatin A-4 disodium, phosphate: effects on radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (1998) 42(4):899-903.
31. SIEMANN DW. MERCER E, LEPLER S, ROJIANI AM: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer (2002) 99(1):1-6.
32. CHAPLIN DJ, HILL SA: The development of combretastatin A4 phosphate as a vascular targeting agent. Int. J. Radiat. Oncol. Biol. Phys. (2002) 54(5):1491-1496.
33. CHAPLIN DJ, HORSMAN MR, TROTTER MJ, SIEMANN DW: Therapeutic significance of microenvironmental factors. In: Medical Radiology, Diagnostic Imaging and Radiation Oncology. Blood perfusion and microenvironment of human tumors. M Molls, P Vaupel (Eds), Springer-Verlag, Berlin, Germany (1998):133-143.
34. HORSMAN MR, MURATA R, BREIDAHL T, NIELSEN FU et al.: Combretastatins: novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv. Exp. Med. Biol. (2000) 476:311-323.
35. LANDUYT W, AHMED B, NUYTS S, THEYS J et al.: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angtogenesis treatment. Int. J. Radiat. Oncol. Biol. Phys. (2001) 49(2):443-450.
36. HORSMAN MR, R MURATA: Combination of vascular targeting agents with thermal or radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (2002) 54(5):1518-1523.
37. PEDLEY RB, HILL SA, BOXER GM, FLYNN AA et al.: Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res. (2001) 61(12):4716-4722.
38. GROSIOS K, LOADMAN PM, SWAINE DJ, PETTIT GR et al.: Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. (2000) 20(1A):229-233.
39. NELKIN BD, BALL DW: Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep (2001) 8(1):157-160.
40. WILDIERS H, AHMED B, GUETENS G, DE BOECK G et al.: Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Eur. J. Cancer (2004) 40(2):284-290.
41. MURATA R, SIEMANN DW, OVERGAARD J, HORSMAN MR: Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother. Oncol. (2001) 60(2):155-161.
42. MURATA R, OVERGAARD J, HORSMAN MR: Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (2001) 51(4):1018-1024.
43. HORSMAN MR, CHRISTENSEN KL, OVERGAARD J: Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int. J. Hyperthermia (1989) 5(2):123-136.
44. EIKESDAL HP, BJERKVIG R, MELLA O, DAHL O: Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors. Radiother. Oncol. (2001) 60(2):147-154.
45. GRIGGS J, HESKETH R, SMITH GA, BRINDLE KM et al.: Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br. J. Cancer (2001) 84(6):832-835.
46. GRIGGS J, SKEPPER JN, SMITH GA, BRINDLE KM et al.: Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am. J. Pathol. (2002) 160(3):1097-1103.
47. NAMBU H, NAMBU R, MELIA M, CAMPOCHIARO PA: Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. (2003) 44(8):3650-3655.
48. STRATFORD MR, DENNIS MF: Determination of combretastatin A-4 and its phosphate ester pro-drug in plasma by high-performance liquid chromatography. J. Chromatogr. B. Biomed. Sci. Appl. (1999) 721(1):77-85.
49. DOWLATI A, ROBERTSON K, COONEY M, PETROS WP et al.: A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. (2002) 62(12):3408-3416.
50. STEVENSON JP, ROSEN M, SUN W, GALLAGHER M et al.: Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. (2003) 21(23):4428-4438.
51. RUSTIN GJ, GALBRAITH SM, ANDERSON H, STRATFORD M et al.: Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. (2003) 21(15):2815-2822.
52. GALBRAITH SM, MAXWELL RJ, LODGE MA, TOZER GM et al.: Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. (2003) 21(15):2831-2842.
53. ANDERSON HL, YAP JT, MILLER MP, ROBBINS A et al.: Assessment of pharmacodynamic vascular response in a Phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. (2003) 21(15):2823-2830.
54. HU E, KO R, KODA R, ROSEN P et al.: Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies. Cancer Chemother. Pharmacol. (1990) 26(5):359-364.
55. SIFTON D, MURRAY L, KELLY G: Physicians' Desk Reference (55th Edition). Medical Economics Company, Inc., Montvale NJ, USA (2001).
56. PLATTS SH, FALCONE JC, HOLTON WT, HILL MA et al.: Alteration of microtubule polymerization modulates arteriolar vasomotor tone. Am. J. Physiol. (1999) 277(1 Pt 2): H100-106.
57. BAZETT HC: An analysis of the time-relations of electrocardiograms. Heart (1920) 7:353-367.
58. FRIDERICIA LS: Die Systolendauer im Electrokardiogramm bei normalen Menchan und bei Herzdranken. Acta Med. Scand. (1920) 53:469-486.
59. HONESS DJ, HYLANDS F, CHAPLIN DJ, TOZER GM: Comparison of strategies to over come the hypertensive effect of Combretastatin A4 phosphate in a rat model. Br. J. Cancer (2002) 86 S166. 278.